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Metastasis from lung adenocarcinoma can occur
swiftly to multiple organs within months of diagnosis.
The mechanisms that confer this rapid metastatic
capacity to lung tumors are unknown. Activation of
the canonical WNT/TCF pathway is identified here as
a determinant of metastasis to brain and bone during
lung adenocarcinoma progression. Gene expression
signatures denoting WNT/TCF activation are associ-
ated with relapse to multiple organs in primary lung
adenocarcinoma. Metastatic subpopulations isolated
from independent lymph node-derived lungadenocar-
cinoma cell lines harbor a hyperactive WNT/TCF
pathway.Reduction ofTCF activity in thesecellsatten-
uates their ability to form brain and bone metastases in
mice, independently of effects on tumor growth in the
lungs. The WNT/TCF target genes HOXB9 and LEF1
are identified as mediators of chemotactic invasion
and colony outgrowth. Thus, a distinct WNT/TCF
signaling program through LEF1 and HOXB9
enhances the competence of lung adenocarcinoma
cells to colonize the bones and the brain.
Foravideosummaryof thisarticle, see thePaperFlick
file available with the online Supplemental Data.
INTRODUCTION
Metastasis is an ominous feature of malignant solid tumors, and
its natural course varies extensively depending on the type of
disease. The tissue and cell of origin of the tumor markedly influ-
ence the sites and severity of distant metastasis. Depending on
the cancer subtype, metastasis may emerge quickly in multiple
organs or in particular organs after a protracted latency period.Breast tumors, for example, undergo dissemination from an
early stage (Husemann et al., 2008; Klein et al., 1999), but metas-
tasis to bones, lungs, brain, or liver may not manifest until years
or decades after the diagnosis and removal of the primary tumor
(Karrison et al., 1999; Schmidt-Kittler et al., 2003). This course
suggests that disseminated breast cells normally require further
malignant evolution to overtly colonize distant organs. This
process gives rise to organ-specific metastatic cell populations,
which has prompted the identification of organ-specific metas-
tasis genes and functions (Nguyen et al., 2009).
Metastasis in other types of cancer follows a different course,
with rapid spread tomultipleorgans.Acase inpoint is lungadeno-
carcinoma, the most common subtype of lung cancer with a high
mortality rate (Hoffman et al., 2000). Even if diagnosed at an early
stageandsurgically removed, lungadenocarcinomascan relapse
within months, spreading to the lymph nodes, contralateral lung,
adrenal glands, the bones, and the brain (Feld et al., 1984; Hess
et al., 2006; Martini et al., 1995). Brain metastasis has particularly
morbid physical and cognitive consequences (Gaspar, 2004;
Gavrilovic and Posner, 2005; Thomas et al., 2000). Lung adeno-
carcinoma is a principal source of brain metastasis, due in part
to the arterial circulation flowing directly from the lungs to the
brain,whichpulmonarycancer cells canmoreeasily access (Gas-
par, 2004; Gavrilovic and Posner, 2005; Thomas et al., 2000).
The genes and mechanisms that mediate lung adenocarci-
noma metastasis are largely unknown. However, the natural
course of this disease suggests the acquisition of mechanisms
in lung adenocarcinoma cells that allow the aggressive infiltration
and colonization of multiple organs soon after cancer cell disper-
sion from a primary tumor. This hypothesis led us to consider the
involvement of developmental pathways as providers of these
functions. By combining genome-wide transcriptional analysis
and experimental modeling, we identified the activation of the
WNT/TCF pathway as a determinant of lung adenocarcinoma
metastatic competence to multiple organ sites.
The WNT signaling pathway plays major roles in stem cell
biology, organogenesis, tissue homeostasis, and cancer (Clevers,Cell 138, 51–62, July 10, 2009 ª2009 Elsevier Inc. 51
Figure 1. A Subset of TCF4 Target Genes Associated with Lung Adenocarcinoma Metastasis
(A) Hierarchical clustering of 107 clinically annotated human lung adenocarcinomas (MSKCC set 1) using a list of 73 TCF4 regulated genes available on the U133A
Affymetrix chip, segregates a set of tumors (red block) with a high proportion of relapses (red bars). R value = 0.73. The bottom row represents themedian expres-
sion value of TCF4 target genes.
(B) Kaplan-Meier curves for metastasis-free survival to all sites according to TCF4 signature.
(C) Metastasis-free prediction of other pathway classifiers inMSKCC set 1 and a cohort of 368 primary breast tumors. The p value in parentheses denotes inverse
correlation. p values were calculated by log rank test.2006; Klaus and Birchmeier, 2008; Logan and Nusse, 2004; Moon
et al., 2004). Binding of secretedWnt ligands toFrizzledandLRP5/
6 transmembrane receptors prevents thephosphorylation-depen-
dent polyubiquitination and degradation of the signaling pool of
b-catenin in the cytoplasm. This degradation is initiated by a
protein complex including APC (the adenomatous polyposis coli
gene product), Axin, and glycogen synthase kinase-3b (GSK-3b)
(Clevers, 2006; Logan and Nusse, 2004). Spared from degrada-
tion, b-catenin accumulates in the nucleus and binds to transcrip-
tion factors of the LEF/TCF (lymphoid enhancer-binding factor and
T cell factor) family to regulate gene expression (Arce et al., 2006).
Mutations that constitutively activate the WNT pathway are
frequently involved in colorectal cancer initiation (Clevers, 2006;
Moon et al., 2004; Morin et al., 1997; Polakis, 2007). However,
such mutations are infrequent in lung adenocarcinomas (Ding
et al., 2008; Mazieres et al., 2005). Prominent tumor-initiating
events in lung adenocarcinoma include KRAS and EGFR muta-
tions (Rodenhuis et al., 1988; Sharma et al., 2007). Surprisingly,
we found that gene-expression signatures denoting WNT/TCF
pathway activity in lung adenocarcinomas are associated with
a high rate of relapse to distant sites. In vivo selection of meta-
static cells from independent human lung adenocarcinoma lines
yieldsderivatives that harbor ahyperactiveWNT/TCFpathway, in
association with an enhanced ability to infiltrate and colonize the
brain and bones. Using these cells as a model, we provide func-
tional evidence for the involvement of twoWNT target genes, the
transcription factors HOXB9 and LEF1, as mediators of chemo-
tactic invasion and colony outgrowth.
RESULTS
ATCF Transcriptional Signature Is Associatedwith Lung
Adenocarcinoma Relapse
Because of the propensity of lung adenocarcinomas to rapidly
metastasize to multiple organs, and the lack of mutations52 Cell 138, 51–62, July 10, 2009 ª2009 Elsevier Inc.associated with this transition thus far, we undertook the
approach of analyzing a clinical cohort of lung adenocarci-
nomas using gene-expression signatures that denote activa-
tion of specific pathways. We utilized gene sets that were
responsive to a K-Ras mutation in a mouse model (Sweet-Cor-
dero et al., 2005), to a dominant-negative TCF4 (dnTCF4) in
colon cancer cells (van de Wetering et al., 2002), to treatment
of epithelial cells with TGF-b (Padua et al., 2008), or to overex-
pression of c-Myc, SRC, or E2F3 in human mammary epithelial
cells (Bild et al., 2006). We queried gene-expression data on
107 annotated primary lung adenocarcinomas including 65
stage I tumors from patients who had relapsed and who re-
mained disease free (MSKCC set 1, Table S1 available online).
In an unsupervised analysis, the TCF4 gene signature identi-
fied a distinct subgroup (Figure 1A) with an elevated rate of
recurrence to multiple organs (Figure 1B, p = 0.006). The
K-Ras, SRC, and E2F3 signatures were not predictive of
increased overall metastasis (Figure 1C). The TGF-b signature,
which is associated with lung relapse in estrogen receptor-
negative breast tumors (Padua et al., 2008) was not specifi-
cally associated with lung adenocarcinoma metastasis,
whereas the MYC signature was modestly predictive (Fig-
ure 1C, p = 0.03). A b-catenin gene set (Bild et al., 2006)
was not associated with relapse (data not shown). This set,
however, largely consists of downregulated genes in the
absence of Wnt signal, potentially reflecting context-specific
b-catenin functions that are independent of TCF transcription
(Gottardi and Gumbiner, 2004). After statistical correction for
multiple comparisons, the TCF4 gene set was the only signif-
icant predictor of relapse (Bonferroni correction, p = 0.042).
Because TCF4 is a member of the LEF/TCF family of WNT
pathway transcriptional effectors (Arce et al., 2006), we postu-
lated that canonical WNT transcriptional activity may distin-
guish a subset of lung adenocarcinomas with high compe-
tence for metastasis.
Figure 2. Experimental Model of Lung Adenocarcinoma Metastasis
(A) In vivo selection scheme for the isolation of metastatic populations (BrM3) from the NCI-H2030 and PC9 lung adenocarcinoma lines.
(B) Shown are representative bioluminescent images (i) of brain, limb and spine metastasis. Brain and bone lesions were confirmed via MRI (ii) and X-ray, respec-
tively (iii).
(C) Kaplan-Meier curves of metastasis incidence (brain and/or bone) in mice inoculated with 104 cells. Parental H2030 cells versus H2030-BrM3 derivatives are
(top) and PC9 parental versus PC9-BrM3 cells (bottom) are shown. p values were calculated by log rank test.
(D) Frequency and distribution of metastasis after inoculation of 5 3 104 cells.
(E) Hematoxylin and eosin (H&E) stain of hind limb. * indicates bone lesions.
(F) H&E stain of osteolytic metastasis (arrows). The scale bar represents 200 mm.
(G) H&E staining of PC9-BrM3 brain metastasis. The scale bar represents 100 mm.
(H) Confocal imaging of H2030-BrM3 cells in the brain (GFP, green), human Ki67 (magenta), CD31+ vasculature (red), and DAPI (blue). Arrows indicate Ki67-posi-
tive tumor cells. The scale bar represents 23 mm.
(I) PC9-BrM3 tumor (GFP, green), surrounded by reactive astrocytes expressing glial fibrillary acidic protein (GFAP, magenta). The scale bar represents 50 mm.
(J) H2030 parental and H2030-BrM3 cells were implanted with Matrigel in the lung via intrathoracic inoculation. Tumors were grown for 6–8 weeks before organs
were extracted and imaged. Left: scatter plot of lung photon flux for parental and BrM3-injected mice with a similar range of lung tumor burden. The absence
(black dot) or presence (red dot) of brain metastasis is noted for each animal. Right: representative images of lungs inoculated with parental (i) or BrM3 (ii) cells
and corresponding brains.
(K) Lung/pleural tumor growth rates were measured after intrathoracic implantation. Data are presented as the normalized mean lung photon flux. Error bars
represent the SEM. p values are based on a two-sided Student’s t test. n, number of animals per cohort.An Experimental Model of Lung
Adenocarcinoma Metastasis
To develop an experimentalmodel for the analysis of lung adeno-
carcinoma metastasis, we isolated metastatic subpopulations
from two human lung cancer cell lines. The H2030 cell line was
established froma lymphnodeof a stage III lungadenocarcinoma
patient and harbors a KRASG12C mutation (Phelps et al., 1996).
The PC9 linewas established froma lymph node of a lung adeno-
carcinoma patient with an EGFRDexon19 mutation (Koizumi et al.,2005; Sasaki et al., 1991). As these two cell lines were derived
from lymph nodes, they provided appropriate systems for the
isolation of malignant cells that might harbor multiorgan meta-
static competence before adaptation to grow in distant organs.
When placed in the arterial circulation of immunodeficient
mice by intracardiac inoculation, both cell lines colonized the
bones and brain. We extracted tumor cells from the brain and
expanded them in culture for twomore rounds of in vivo selection
(Figure 2A). The resulting BrM3 cell populations consistentlyCell 138, 51–62, July 10, 2009 ª2009 Elsevier Inc. 53
demonstrated enrichedmetastatic activity, as detected by biolu-
minescence imaging (BLI) and magnetic resonance of the brain
or X-ray imaging of the bones (Figure 2B). H2030-BrM3 and
PC9-BrM3 cells formed brain metastasis in 100% of animals
compared to a 10%–13%efficiency of the parental lines (Figures
2C and 2D). Although isolated from the brain, the H2030-BrM3
and, to a lesser extent, PC9-BrM3 cells showed an increased
ability to colonize the vertebral and limb bones over their starting
metastatic potential (Figure 2D). Thus, the ability to metastasize
to bone and brain are linked in the BrM3 derivatives.
In the bones, PC9-BrM3 and H2030-BrM3 formed osteolytic
lesions (Figures 2E and 2F). PC9-BrM3 and H2030-BrM3 cells
avidly colonized the cerebrum and cerebellum, forming nodules,
as well as smaller invasive lesions with occasional spread into
the meninges (Figure 2G and Figure S1A). Invasive metastases
in the brain were not angiogenic, but displayed perivascular
localization and proliferation (Figure 2H), with gliosis (Figure 2I)
and astrocyte proliferation at the invasive edge of metastasis
(Figure S1B). Importantly, H2030-BrM3 cells implanted ortho-
topically in the lung could disseminate to the brain independently
of lung and pleural tumor burden (Figure 2J).
BrM3 cells did not proliferate faster than their parental popula-
tions inmonolayer culture, norwere theymore resistant to growth
factor depletion (Figures S2A and S2B). When implanted with
extracellular matrix Matrigel directly into the lungs, H2030-
BrM3 cells had an initial growth advantage (Figure 2K, left),
whereas PC9-BrM3 cells did not have altered tumorigenic rates
compared to their parental counterparts (Figure 2K, right). Similar
results were obtained from subcutaneously implanted tumors
(data not shown). The advantage of H2030-BrM3 cells is consis-
tent with their enhanced colony-forming ability in Matrigel (see
below). However, the subsequent expansion rate of H2030-
BrM3 tumors in the lung over 7 weeks was not significantly
different from those of the parental line (Figure 2K, left). In sum,
these two lung adenocarcinoma models recapitulate salient
features of metastasis from lung adenocarcinoma, including the
capacity to rapidly disseminate and colonize bone and brain.
Deregulated WNT/TCF Activity in Highly Metastatic
Lung Adenocarcinoma Cells
We analyzed the transcriptome of the parental and BrM3 deriv-
atives under basal cell culture conditions. The PC9-BrM3 tran-
scriptome was significantly enriched for the TCF4 classifier,
and the H2030-BrM3 cells showed a detectable albeit not statis-
tically significant enrichment (Figure 3A). To evaluate the overall
activity of WNT/TCF pathway in these cell lines, we performed
transcriptional reporter assays using the TOP/FOP reporter
system (Korinek et al., 1997). The BrM3 cells in both systems
showed higher basal TCF transcriptional activity (2-fold and
2.8-fold, respectively) than the corresponding parental lines
(Figure 3B). Furthermore, addition of the ligand Wnt3A caused
a strong increase in TCF activity in the BrM3 subpopulations,
which significantly surpassed the Wnt3a-induced increase in
the parental lines (Figure 3B). These results revealed the
presence of a deregulated TCF pathway in both metastatic cell
populations.
b-catenin is distributed as an abundant membrane associated
pool and a free labile pool available for WNT/TCF signaling. The54 Cell 138, 51–62, July 10, 2009 ª2009 Elsevier Inc.stabilization and nuclear localization of this free pool are neces-
sary for b-catenin as a coactivator of TCF-dependent transcrip-
tion (Clevers, 2006; Klaus and Birchmeier, 2008; Logan and
Nusse, 2004; Moon et al., 2004). Immunoblotting analysis
revealed nuclear accumulation of b-catenin after Wnt3a treat-
ment in all adenocarcinoma lines (Figure 3C). Notably, both the
cytosolic and nuclear/signaling levels of b-catenin were higher
in BrM3 cells than in parental H2030 cells (Figure 3C). Phosphor-
ylation of b-catenin at Ser33/37 and Thr41 marks the signaling
pool for proteosomal degradation (Clevers, 2006). Upon Wnt3A
stimulation, b-catenin was more rapidly dephosphorylated at
Ser33/37 and Thr41 in H2030-BrM3 cells, indicating a greater
rate of stabilization (Figure 3D). In the PC9 derivatives, b-catenin
was abundant in both parental and BrM3 cells, suggesting
the preexistence of a hyperactive WNT pathway (Figure 3C).
Dephosphoryation of Ser33/37 and Thr41 in response to
Wnt3a was similar in the parental and BrM3 PC9 lines, suggest-
ing that enhanced TCF activity in PC9-BrM3 cells may depend
on additional alterations (Figure 3D).
Somaticmutations inAPC or the b-catenin gene (CTNNB1) can
increase b-catenin stability and activity in colorectal cancer
(Clevers, 2006; Moon et al., 2004; Morin et al., 1997; Polakis,
2007). Mutations in these genes have been detected at low
frequency in lung adenocarcinomas (Ding et al., 2008). In BrM3
and parental sets, we sequenced APC, CTNNB1, and 13 addi-
tional genes (APC2, AXIN1, AXIN2, GSK3B, STK11, LEF1, TCF7/
TCF1, TCF7L1/TCF3, TCF7L2/TCF4, FRZB, SFRP1, SFRP2, and
SFRP4) that encode proximal components of the WNT pathway.
No mutations were found to be specifically associated with
BrM3 populations, except for a silent mutation in SFRP4 (G to A,
chromosome 7: 37918251) in H2030-BrM3 cells. qRT-PCR and
GeneChip array analysis of 84 WNT pathway-related genes
(including those sequenced) revealed a common upregulation of
LEF1 in highly metastatic cells (Figures 3E and 3F), with less
consistent alteration in the expression of the other genes (data
not shown). These results suggest that hyperactivation of WNT/
TCF in these metastatic cells is not due to mutations in core
components of the WNT pathway but to other alterations that
commonly converge on WNT transcriptional effectors.
A Lung Adenocarcinoma WNT Gene Response
Associated with Metastasis
Because the TCF4 signature was obtained from a colon cancer
cell line (van de Wetering et al., 2002) we asked whether the
metastatic potential of lung adenocarcinomas also correlates
with WNT gene-expression responses derived specifically from
lung adenocarcinoma cells. We generated transcriptomic gene
sets from Wnt3a-treated versus untreated cells in both the
H2030 and PC9 systems, combining the responses in both
parental and metastatic derivatives. To obtain a more compre-
hensive transcriptional readout, we employed approaches
based on a correlation coefficient method (Chang et al., 2005;
Xu et al., 2008). With this method, the expression trends of
many pathway-associated genes can be converted into a contin-
uous score that avoids arbitrary expression level criteria and is
applicable across multiple data sets.
When tested in our 107 tumor lung adenocarcinoma cohort,
the resulting H2030 and PC9 WNT-responsive gene sets were
Figure 3. WNT/TCF Activity Is Deregulated in Metastatic Lung Adenocarcinoma Cells
(A) Expression of the TCF4 classifier in duplicate samples (a and b) of the indicated derivatives is presented as a heat map. The bottom row represents themedian
expression of the TCF4 signature. p values are from a t test comparing median expression.
(B) Normalized luciferase measurements of specific TOP-FLASH over nonspecific FOP-FLASH activity (TOP/FOP RLU), in derivatives that were mock treated or
stimulated with recombinant Wnt3A for 12 hr. Error bars represent the SEM. p values are based on a two-sided Student’s t test.
(C) Denoted cells were treated with Wnt3a for 0, 1, 3, and 6 hr. Immunoblots were performed for cytosolic (top) or nuclear (bottom) b-catenin, a-tubulin, and
histone H1.
(D) Cells were treated with Wnt3a for 0, 30, and 90 min. Overall b-catenin protein levels and its ser33/37/Thr41-phosphorylated form were determined by immu-
noblot.
(E) Basal expression of LEF1 and APC. Error bars indicate 95% confidence interval from triplicate qRT-PCR samples.
(F) Immunoblot for LEF1 protein.independently associated with metastatic recurrence to multiple
organ sites (Figures S3A and S5B). PC9 and H2030 cells express
WNT-responsive genes which only partial overlap. These differ-
ences may reflect pathway activation in the context of different
tumor developmental histories. To derive a broader WNT/TCF
pathway classifier from these two gene sets, we combined
probe sets that were regulated by Wnt3a in at least one experi-
mental system with similar expression trends in the other and
which were still associated with clinical outcome in MSKCC
set 1 (refer to the Experimental Procedures). This yielded a
lung cancer WNT gene set (LWS), consisting of 91 probes sets
including 81 known genes (Table S2).
The LWS displayed improved prediction of metastatic relapse
compared to the TCF4 classifier in the initial cohort of primarylung adenocarcinomas (MSKCC set 1, p = 0.001; Figure 4A)
and, notably, in an independent lung adenocarcinoma data set
(MSKCCset 2, p = 9.63 105; Figure 4A) and among lung adeno-
carcinomas in a cohort of mixed lung tumors (SMC set, p =
0.0025; Figure 4B). The LWS was associated with recurrence in
stage I lung adenocarcinomas (Figure 4C), and did not predict
metastasis in squamous lung carcinomas (Figure 4B) or in breast
carcinomas (Padua et al., 2008) (Figure 4D). Consistent with our
model systems, the LWSpredicted distant lung adenocarcinoma
relapse to both brain and bone (Figures S3C and S3D). Although
the H2030-BrM3 or PC9-BrM3 were brain isolates, we were
unable to obtain from these cells a commonsignature thatwould-
predict brain relapse with methods that previously revealed
organ-specific metastasis signatures (Bos et al., 2009; MinnCell 138, 51–62, July 10, 2009 ª2009 Elsevier Inc. 55
Figure 4. A Specific WNT-Responsive Gene
Set Associated with Lung Adenocarcinoma
Metastasis
Independent transcriptional predictors from
H2030 and PC9 derivatives were obtained by
comparison of Wnt3a activated with unstimulated
cells and were combined to yield the lung cancer
WNT-responsive gene set (LWS).
(A) Kaplan-Meier curves for metastasis-free
survival based on LWS expression in MSKCC set
1 and MSKCC set 2. Green, LWS negative; red,
LWS positive.
(B) Performance of the LWS in the Samsung
Medical Center (SMC) set, including a mix of
adenocarcinomas and squamous carcinomas of
the lung.
(C) LWS prediction of relapse was observed in
stage I lung adenocarcinomas.
(D) Performance of the LWS in a combined
MSKCC-EMC cohort of 368 primary breast
cancers. A log rank test was used to determine p
values in (A)–(D).
(E) The LWSwas converted into a Pearson correla-
tion coefficient score that compares the degree of
correlation for LWS expression betweenWNT acti-
vated cell lines, primary adenocarcinomas that
included clinical annotation within 5 years (43
recurrences and 53 non recurrences), and 28 brain
metastases. Data are presented as a Box-whisker
plot. p values were calculated by Student’s t test.et al., 2005a). To determine the association of LWS status with
overall patient survival, we tested four independent stage I lung
adenocarcinoma cohorts from a multi-institutional study (Shed-
den et al., 2008). In three out of the four cohorts tested, the
LWSpredicted poor survival in stage I adenocarcinomas (Figures
S4A–S4E). Altogether, these results demonstrate an association
of WNT hyperactivation with distant multiorgan metastatic
potential of lung adenocarcinomas.
By using the LWS in a Pearson correlation coefficient score,
we compared brain samples from lung adenocarcinoma patients
(n = 28; Figure 4E) to either primary lung adenocarcinomas from
patients who remained disease free over 5 years (n = 53) or
primary lung adenocarcinomas from patients who recurred in
any site (n = 43). Lung adenocarcinoma metastases to bone
are rarely resected, andwere not available for study. The expres-
sion trends of LWS genes in brain metastases resembled more
closely primary adenocarcinomas that recurred (Figure 4E).
Thus, the activation of WNT/TCF appears to be maintained
during brain metastatic progression in clinical samples.
LEF1 and HOXB9 are WNT/TCF Targets
that Mediate Metastasis
To evaluate the functional role of WNT/TCF signaling in lung
adenocarcinoma metastasis, we disrupted this pathway by
expressing dominant-negative TCFs (dnTCF1 and/or dnTCF4)
that lack the N-terminal binding site for b-catenin (van de Weter-
ing et al., 2002). Stable expression of dnTCF4 in H2030-BrM356 Cell 138, 51–62, July 10, 2009 ª2009 Elsevier Inc.cells partially decreased the TCF activity (Figures S5A and S5B)
and metastatic activity of these cells (Figure 5A). Coexpression
of dnTCF1 and dnTCF4 in PC9-BrM3 cells (Figures S5C and
S5D) abated the metastatic activity of these cells in different
organs in the same mouse (Figure 5B). Partial reduction in TCF
activity had little effect on BrM3 pulmonary growth (Figures 5C
and 5D).
To identify specificmediators ofWNT prometastatic functions,
we focused on a subset of LWS genes whose expression level
was strongly correlated with the metastatic potential of our cell
derivatives and are implicated in developmental programs.
Three genes that fulfilled these criteria were lymphoid enhancer-
binding factor 1 (LEF1), homeobox B9 (HOXB9), and bone
morphogenetic protein 4 (BMP4). HOXB9 is a TCF4 target (Hat-
zis et al., 2008) and belongs to the homeobox transcription factor
gene family, which is critical for embryonic segmentation and
limb patterning (Abate-Shen, 2002). LEF1 encodes a transcrip-
tional effector of the canonical WNT pathway and is a target of
Wnt3a and TCF4. LEF1 upregulation byWNTmaymediate signal
amplification during malignancy (Hovanes et al., 2001). BMP4
belongs to the TGF-b superfamily, can be induced by WNT,
and regulates stem cell differentiation and multiple develop-
mental processes (Shu et al., 2005; ten Dijke et al., 2003; Varga
and Wrana, 2005).
The expression level of LEF1 and HOXB9 was marginal in
parental H2030 cells, but was increased and potently induced
by Wnt3a in the H2030-BrM3 cells (Figure 5E). In parental PC9
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Figure 5. LEF1 and HOXB9 Are Targets of the Metastatic WNT/TCF Pathway
(A) Kaplan-Meier curves for metastasis after inoculation of 5 3 104 cells stably expressing an empty vector control or dominant-negative TCF4 (dnTCF4), with
representative bioluminescent images.
(B) Control or dnTCF1 and dnTCF4 were expressed in PC9-BrM3 cells. Metastasis was assayed as in (A). p values are based on log rank test.
(C) Lung/pleural tumor growth of H2030-BrM3 cells expressing an empty vector or dnTCF4 as in Figure 2K.
(D) Similar experiments were performedwith control and dnTCF1/4-expressing PC9-BrM3 cells. Error bars represent the SEM. p values are based on a two-sided
Student’s t test.
(E) LEF1 and HOXB9 expression were measured via qRT-PCR after Wnt3A stimulation for 0, 3, and 6 hr. Error bars indicate 95% confidence interval from
replicates.
(F) The indicated lines were treated with Wnt3A for 3 hr, and levels of LEF1 and HOXB9 were determined as in (E).cells, Wnt3a addition augmented the expression level of LEF1
and HOXB9, whereas these genes were highly expressed and
no further inducible by Wnt3a in PC9-BrM3 cells (Figure 5E).
Expression of dnTCFs decreased the expression of LEF1 and
HOXB9 in BrM3 cells (Figure 5F). Thus, the response patterns
of LEF1 and HOXB9 are consistent with a constitutive hyperac-
tivation of WNT/TCF signaling in PC9 cells and a hypersensitivity
to Wnt stimulation in H2030 cells (refer to Figures 3C and 3D).
To achieve specific inhibition of putative WNT/TCF prometa-
static genes, we decreased LEF1 orHOXB9 by stable RNA inter-
ference (RNAi)-mediated knockdown in BrM3 derivatives
(Figure S6A). Knockdown of LEF1 or HOXB9 significantly
decreased the ability of H2030-BrM3 and PC9-BrM3 cells to
form bone and brain metastases (Figures 6A and S6B). Knock-down of BMP4 had no effect on metastasis (data not shown).
Reduction of LEF1 or HOXB9 did not affect the growth of PC9-
BrM3 cells implanted in the lung (Figure S7A). In H2030-BrM3
cells, HOXB9 knockdown did not affect lung and pleural
growth rates, whereas LEF1 knockdown had a partial inhibitory
effect (Figure S7B). These results are consistent with the
tumor reinitiating advantage of H2030-BrM3 but not PC9-BrM3
cells over their parental counterparts (refer to Figure S2D). More-
over, overexpression of LEF1 and HOXB9 in the parental H2030
and PC9 cell lines increased their metastatic activity from circu-
lation to bone and brain (Figures S8 and 6B–6E). Collectively,
these results suggest that HOXB9 and LEF1 can enhance
the competence of lung adenocarcinoma for brain and bone
metastasis.Cell 138, 51–62, July 10, 2009 ª2009 Elsevier Inc. 57
Figure 6. LEF1 and HOXB9 Mediate Metastasis
(A) Kaplan-Meier curves of overall metastasis incidence, for H2030-BrM3 cells encoding control or independent hairpins (sh-a and sh-b) against LEF1 orHOXB9.
Left: Metastasis in mice inoculated arterially with H2030-BrM3 control, BrM3-shLEF1-a, or BrM3-shLEF1-b cells. Right: H2030-BrM3 control cells versus
shHOXB9-a or shHOXB9-b cells.
(B) H2030 parental cells overexpressing either empty vector control or LEF1 andHOXB9were inoculated at 53 104 cells/mouse, and overall metastasis incidence
quantified as in (A).
(C) A similar experiment was performed with PC9 parental lines overexpressing empty vector or LEF1 and HOXB9.
(D) Brain tissue from animals inoculated with the indicated lines. Brown, GFP+ tumor foci. Scale bars represent 200 mm.
(E) Typical hind limbs extracted from animals inoculated with the indicated lines and that had detectable luminescent signal. * indicates bone lesions. Scale bars
represent 500 mm. p values are based on log rank test.LEF1 and HOXB9 as Mediators of Colony Outgrowth
and Chemotactic Cell Invasion
Thebiological propertiesof LEF1andHOXB9were further studied
ex vivo with the H2030-BrM3 population, which has a low
threshold for exogenous WNT activation. Given the link between
WNT/TCF and metastasis to multiple organs, we focused on the
general functions of metastatic outgrowth and invasion. Knock-
down of LEF1 and HOXB9 did not affect general cell viability in
monolayer culture (Figures S2A and S2B). However, when
cultured in Matrigel, H2030-BrM3 cells formed colonies that
grew larger in size (Figure 7A) and in number compared to the
parental H2030 cells (Figure 7B, black bars). Wnt3a addition
further increased the colony outgrowth (Figure 7B, yellow bars),
consistent with the tumor reinitiation advantage of these cells
when implanted in the lung. Interestingly, knockdown of LEF1
expression decreased the size (Figure 7A) and number of the
metastatic H2030-BrM3 colonies (Figure 7B), whereas decreas-
ing HOXB9 expression had no effect.
To analyze metastatic invasion, we measured the infiltration of
these cells through Matrigel in a modified Boyden chamber
assay (Figure 7C). Parental H2030 and H2030-BrM3 cells
showed a similar basal ability to infiltrate Matrigel (Figure 7D).
However, given the strong astrocytic reaction elicited at the inva-
sive edge of metastatic lesions in vivo (refer to Figure 2I), we
repeated the invasion assays using astrocyte-conditionedmedia
as a source of chemoattractant in the bottom chamber. Under58 Cell 138, 51–62, July 10, 2009 ª2009 Elsevier Inc.these conditions, the invasive activity of H2030-BrM3was signif-
icantly higher than that of parental cells (Figure 7D). Preincuba-
tion of H2030-BrM3 cells with Wnt3a increased their invasion
toward stromal conditioned media (Figure 7D, blue bars). Wnt
ligand stimulated the invasion of the parental PC9 cells, while
PC9-BrM3 cell displayed higher basal invasiveness (Figure S9),
consistent with their expression of LEF1 and HOXB9. Wnt3a
did not act as a chemoatractant, since invasion was unaffected
by the addition of Wnt3a to the bottom chamber (data not
shown). Notably, short hairpin RNA (shRNA)-mediated knock-
down of either LEF1 or HOXB9 inhibited invasion in H2030-
BrM3 and PC9-BrM3 cells (Figure 7E). The metastatic potential
of BrM3 cells and their responsiveness to WNT activation were
not associated with changes in the TCF target c-myc, nor were
these phenotypes consistently linked to markers of epithelial-
mesenchymal transition, such as E-cadherin or vimentin expres-
sion (Figure S10).
DISCUSSION
The evidence presented here suggests that a hyperactive WNT/
TCF pathway enhances the ability of human lung adenocarci-
nomas to develop brain and bone metastases. Two WNT target
genes, LEF1 and HOXB9, are identified as promoters of lung
adenocarcinomametastasis andmediators of chemotactic inva-
sion and colony outgrowth. These findings provide insights into
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Figure 7. LEF1 and HOXB9 Potentiate Metastatic Outgrowth and Chemotactic Invasion
(A) The indicated lines were plated into Matrigel, and 103 images of colonies were captured after 10 days in serum-containing media, in the presence or absence
of Wnt3a. The inset shows representative colonies at 203.
(B) Quantification of colonies in the absence (black) or presence (yellow) of Wnt3A.
(C) Schematic of invasion assay. Parental and metastatic BrM3 cells were mock (black) or Wnt3a stimulated (blue) and seeded into transwell inserts layered with
Matrigel. Assays were performed in the presence of control () or astrocyte-conditioned (+)media in the bottom chamber.
(D) Quantification was normalized to the invasion of untreated parental cells.
(E) Cells were stimulated with Wnt3A and used as in (C), with astrocyte chemoattractant. Invasion of the indicated knockdown cells relative to their respective
BrM3 control cells is shown. Error bars indicate the SEM. p values were calculated based on a two-sided Student’s t test.
(F) Model depicting the roles of LEF1 and HOXB9 within a WNT/TCF program that drives early multiorgan metastasis in lung adenocarcinoma.the determinants of the typically rapid, multiorgan metastatic
progression of this disease.
WNT/TCF Signaling Mediates Lung
Adenocarcinoma Metastasis
We derived a lung cancer WNT gene response (LWS) that
can identify lung adenocarcinomas with aggressive biological
characteristics and poor clinical outcome. WNT/TCF pathway
activation as detected by gene expression is associated with
metastasis to brain and bones, two prominent sites of distant
relapse in lung adenocarcinoma, and distinguishes early stage
I lung adenocarcinomas from patients that are most likely to
progress in independent cohorts. However, it does not predict
relapse in squamous lung carcinoma or breast carcinoma. The
transcriptional output of WNT activation is context dependent
(Clevers, 2006; Logan and Nusse, 2004), and otherWNT compo-
nents or different pathway combinations may also contribute
to lung cancer progression with poor prognosis. Nevertheless,
our evidence indicates a unique association between the
WNT/TCF pathway and metastatic propensity in human lung
adenocarcinomas.
Hyperactivation of WNT/TCF is a uniform property of highly
metastatic subpopulations that we obtained from different
human lung adenocarcinoma cell lines. These cells lines corre-
spond to two defined subtypes of lung adenocarcinoma—the
EGFR and KRAS molecular subtypes. KRAS and EGFR muta-tions are present in approximately 25% and 20% of human
lung adenocarcinomas, respectively (Rodenhuis et al., 1988;
Sharma et al., 2007), and have been validated as oncogenes.
However, lung adenocarcinomas initiated by these mutations
require additional alterations in order to metastasize to distant
sites (Ji et al., 2006; Johnson et al., 2001; Politi et al., 2006).
The fact that these cell lines were derived from lymph node
samples suggests that the acquisition of a hyperactive WNT/
TCF pathway within a subset of malignant cells preceded their
colonization of distant organs.
The hyperactivation of WNT/TCF in our model of metastatic
lung adenocarcinomas does not correlate with a preponderance
of typical somatic mutations in this pathway. Mutations in
WNT pathway components are common tumor-initiating events
in colorectal and gastric cancers but are less frequent in lung
adenocarcinomas (Ding et al., 2008). Deregulation of this
pathway may result from additional epigenetic alterations. Inter-
estingly, the silencingofWNTantagonist hasbeen reported incell
lines, as well as tumors from early-stage and relapsing NSCLC
patients (Brock et al., 2008; Licchesi et al., 2008; Mazieres
et al., 2005). While the diverse mechanisms that regulate the
WNT pathway in our models remain to be elucidated, an end
result of this process is the elevated expression of at least two
transcription factors, LEF1 and HOXB9, that encode different
prometastatic functions, some of which are not required for
tumor growth in the lung. The activation in primary tumors ofCell 138, 51–62, July 10, 2009 ª2009 Elsevier Inc. 59
prometastatic functions that provide no local growth advantage
is not without precedent (Karnoub et al., 2007; Padua et al.,
2008). The hyperactivity of theWNT/TCF pathway in lung adeno-
carcinomas observed here might reflect a presence of Wnt
ligands in the primary tumor stroma, a feature of the tumor cell of
origin, an epigenetic bystander alteration of WNT/TCF pathway
components, or a combination of these mechanisms.
LEF1 and HOXB9 Are Effectors of the WNT
Metastasis Program
LEF1 and HOXB9 are direct transcriptional targets of the TCF4
transcription factor (Hatzis et al., 2008). HOXB9 is part of
a homeobox family gene cluster whose expression is normally
restricted toembryogenesis (Abate-Shen, 2002).HOXB9expres-
sion has been reported in lung cancer cell lines (Calvo et al.,
2000), but its function is unknown. LEF1 is a prototypical tran-
scriptional mediator of WNT gene response, and its activation
may amplify pathological WNT signaling (Hovanes et al., 2001).
Moreover, LEF1 can interact with cofactors independently of
b-catenin (Arce et al., 2006). High basal levels of LEF1 in meta-
static cells may increase transcriptional activation without
additional changes in b-catenin.
In our lung adenocarcinomamodel, WNT/TCF hyperactivation
can stimulate bone and brain metastasis independently of
changes in intrinsic tumor cell viability or of a general growth
advantage. We show that HOXB9 and LEF1 increase cancer
cell invasion and that LEF1 promotes tumor colony outgrowth
in extracellular matrix. Interestingly, the phenotype of our meta-
static derivatives resembles that described for bronchioalveolar
stem cells (BASCs) (Kim et al., 2005), which exhibit enhanced
WNT activity after injury (Zhang et al., 2008). Thus, HOXB9 and
LEF1 may fulfill progenitor cell functions that are reenacted
during metastatic progression. The stem cell reprogramming
gene c-MYC is a target of the LEF/TCF pathway in colon cancer
cells (He et al., 1998) but does not correlate with the metastatic
potential of the lung adenocarcinoma lines studied here.
However, we do not exclude the possible involvement of other
WNT target genes in lung adenocarcinoma metastasis.
Early Metastatic Competence versus Progressive
Metastatic Speciation
The present findings illuminate a central concept in lung adeno-
carcinoma progression, namely, the role of a prometastatic
signal that is gradually increased in primary tumors and enables
their rapid metastatic spread. Unlike breast or prostate cancer
metastasis, which may develop years to decades after the
removal of a primary tumor, lung adenocarcinomas are typically
competent to metastasize rapidly to multiple organs. The long
latency of metastasis in breast or prostate carcinoma implies
the need for further malignant evolution of the disseminated
cancer cells in the infiltrated organs. In contrast to the protracted
evolution of cancers which undergo long periods of remission
before clinical metastasis, the short latency of relapse in lung
adenocarcinomas predicts their acquisition of a prometastatic
program early on and a lesser degree of organ speciation. Our
identification of a mechanism that provides overall metastatic
competence in early stage lung adenocarcinomas is in agree-
ment with these predictions.60 Cell 138, 51–62, July 10, 2009 ª2009 Elsevier Inc.Intracranial relapses are a significant source of failure after
treatments with chemotherapy (Chen et al., 2007) and targeted
drugs (Omuro et al., 2005). While animal models of lung cancer
represent a critical venue to address this problem, genetically
modified mouse models of lung cancer reported to date yield
metastatic tumors that occur in visceral organs but not in the
brain (Jackson et al., 2005; Zheng et al., 2007). While not without
limitations, our experimental systems recapitulate important
phenotypic and molecular features of lung adenocarcinoma,
including brain and bone metastasis, and a hyperactive WNT/
TCFpathway in thebackgroundof relevant oncogenicmutations.
Thismodelmaybeuseful for achievingadeeper understandingof
early metastatic events and the development of improved treat-
ments for lung adenocarcinoma patients at risk for metastasis.
EXPERIMENTAL PROCEDURES
Additional methods for cell culture, in vivo selection, in vitro assays, immunos-
taining procedures, retroviral shRNA targets, sequencing, and gene expres-
sion analysis are provided in the Supplemental Data.
Animal Studies
Animal procedures were in accordance with the MSKCC Institutional Animal
Care and Use Committee. Xenografts were performed on mice with SCID
mutation in a nonobese diabetic background (NOD.SCID) or on mice carrying
the nude mutation crossed to the CBA/N X chromosome-linked immune
defect and beige mutations (bg-nu-Xid). Animals were aged matched between
4 and 6 weeks. NSCLC cell lines were engineered to stably express a triple
modality vector encodingGFP-luciferase fusion (Minn et al., 2005b). For exper-
imental metastasis assays, between 104 and 105 cells were resuspended in
0.1 ml PBS and injected into the right ventricle. Metastasis was detected by
bioluminescence with an IVIS 200 Xenogen and confirmed by X-ray, MRI,
and/or histology. Incidence of metastasis was quantified on the basis of the
luminescent signal in limbs and/or brain at a given time point and presented
as Kaplan-Meir curves. For lung tumorigenesis, 104 cells were resuspended
in a 1:2 mixture of PBS and growth factor-reduced Matrigel (BD Biosciences)
and injected into the lung through the left rib cage of mice as previously
described (Doki et al., 1999). Alternatively, cells were injected into the lateral
tail vein. Growth rate in the lung/pleura was measured as a function of lung
photon flux normalized to day 0 in live animals. Tumorigenic growth rates
were similar when implanted subcutaneously. Metastasis phenotype was
independent of animal sex.
LEF/TCF Reporter Assays
The TOP-Flash and FOP-Flash promoters were subcloned into pGL4.82-
Renilla luciferase constructs (Promega). Cells were transfected with Lipofect-
amine 2000 and selected for 2 days in puromicin. Transfected cell were then
reseeded into 24 well plates at 50,000 cells/well before treatment with
recombinant Wnt3a (50100 ng/ml; R&D Systems) for 12 hr. Reporter assays
were performed according to the manufacturer’s instructions (Promega).
Promoter activity was calculated as the ratio of specific TOP-Flash over
nonspecific FOP-Flash relative renilla luciferase units (RLU).
Gene Expression Profiling
Subconfluent parental and metastatic derivatives were serum starved over-
night and either mock treated or stimulated with recombinant Wnt3A
(75–100 ng/ml) for 3 hr. RNA was extracted from duplicate samples of each
condition using the RNeasy mini kit (QIAGEN). Labeling and hybridization of
the cell line samples to the HG-U133A_2 gene expression chip (Affymetrix)
was performed by the MSKCC Genomics Core Facility. Microarray data
from a cohort of 107 lung adenocarcinoma tumors (MSKCC set 1), a second
cohort of 129 adenocarcinomas (MSKCC set 2) including tumors from
Chitale et al. (2009), and 28 brain metastasis were analyzed on Affymetrix
HG-U133A and HG-U133A_2 platforms. A third data set containing a mix of
lung adenocarcinomas and squamous carcinomas from the SamsungMedical
Center (SMC set; HG-U133A Plus 2.0) was publicly available. For pathway and
correlation coefficient analysis, raw CEL data were preprocessed with RMA
algorithm implemented by the affy package of R statistical software (desig-
nated as R hereafter). Gene expression data of cell derivatives are deposited
at GEO (GSE14107). Samsung Medical Center set was obtained from GEO
(GSE8894). Raw data and clinical annotation for MSKCC sets 1, 2, and brain
metastasis are available at http://cbio.mskcc.org/Public/lung_array_data/.
Pathway Signature Derivation
Genes regulated by KRAS and dnTCF4 were extracted from published results
(Sweet-Cordero et al., 2005; van de Wetering et al., 2002) and matched to the
corresponding Affymetrix probes (HG-U133A platform). The Affymetrix version
of the TCF4 signature was used to cluster MSKCC set 1 in an unsupervised
manner (by the ‘‘heatmap.2’’ function of ‘‘gplots’’ package of R). The cluster
that overexpresses the majority of dnTCF4 genes was defined as TCF4+,
and the other cluster was defined as TCF4. The clinical outcomes of the
two clusters were compared by log-rank test with the ‘‘survdiff’’ function of
‘‘survival’’ package of R. b-catenin, c-myc, SRC, E2F3, and TGF-b gene lists
were obtained from previous results (Bild et al., 2006; Padua et al., 2008)
and used for unsupervised analysis.
Derivation and Characterization of a Lung Cancer
WNT Gene Response Set
A combinatory approach based on correlation coefficient score and unsuper-
vised clustering was used to evaluate the association between Wnt3A-medi-
ated gene responses in lung adenocarincoma cell lines and relapse in MSKCC
sets 1, 2, and SMC lung adenocarcinoma clinical cohorts. This was confirmed
by pathway meta-analysis. A comprehensive description of these methods is
provided in the Supplemental Data.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, two
tables, ten figures, and video summary and can be foundwith this article online
at http://www.cell.com/supplemental/S0092-8674(09)00455-3.
ACKNOWLEDGMENTS
Wewould like to express deep gratitude to our late colleagueWilliam L. Gerald.
We are indebted to H. Varmus, W. Pao, V. Rusch, and members of the Mas-
sague´ laboratory for insightful discussions. We thank A. Heguy for supervising
sequencing and mutational analysis. H. Clevers, E. Batlle, R. Moon, W. Pao,
and H. Varmus generously provided constructs and cell lines. This work was
supported by the Alan and Sandra Gerry Metastasis Research Initiative and
National Institutes of Health grant P01-129243 (M.G.K., M.L., W.L.G., and
J.M.). D.X.N. was the Bayer postdoctoral fellow of the Damon Runyon Cancer
Research Foundation. A.C.C. was supported by an American Society of
Clinical Oncology Career Development Award. J.M. is an Investigator of the
Howard Hughes Medical Institute.
Received: August 4, 2008
Revised: December 12, 2008
Accepted: April 7, 2009
Published online: July 2, 2009
REFERENCES
Abate-Shen, C. (2002). Deregulated homeobox gene expression in cancer:
cause or consequence? Nat. Rev. Cancer 2, 777–785.
Arce, L., Yokoyama, N.N., and Waterman, M.L. (2006). Diversity of LEF/TCF
action in development and disease. Oncogene 25, 7492–7504.
Bild, A.H., Yao, G., Chang, J.T., Wang, Q., Potti, A., Chasse, D., Joshi, M.B.,
Harpole, D., Lancaster, J.M., Berchuck, A., et al. (2006). Oncogenic pathway
signatures in human cancers as a guide to targeted therapies. Nature 439,
353–357.Bos, P.D., Zhang, X.H.F., Nadal, C., Shu,W., Gomis, R.R., Nguyen, D.X., Minn,
A.J., Van de Vijver, M., Gerald, W.L., Foekens, J.A., et al. (2009). Genes that
mediate breast cancer metastasis to the brain. Nature, in press. Published
online May 6, 2009. 10.1038/nature08021.
Brock, M.V., Hooker, C.M., Ota-Machida, E., Han, Y., Guo, M., Ames, S.,
Glockner, S., Piantadosi, S., Gabrielson, E., Pridham, G., et al. (2008). DNA
methylation markers and early recurrence in stage I lung cancer. N. Engl.
J. Med. 358, 1118–1128.
Calvo, R., West, J., Franklin, W., Erickson, P., Bemis, L., Li, E., Helfrich, B.,
Bunn, P., Roche, J., Brambilla, E., et al. (2000). Altered HOX and WNT7A
expression in human lung cancer. Proc. Natl. Acad. Sci. USA 97, 12776–12781.
Chang, H.Y., Nuyten, D.S., Sneddon, J.B., Hastie, T., Tibshirani, R., Sorlie, T.,
Dai, H., He, Y.D., van’t Veer, L.J., Bartelink, H., et al. (2005). Robustness, scal-
ability, and integration of a wound-response gene expression signature in
predicting breast cancer survival. Proc. Natl. Acad. Sci. USA 102, 3738–3743.
Chen, A.M., Jahan, T.M., Jablons, D.M., Garcia, J., and Larson, D.A. (2007).
Risk of cerebral metastases and neurological death after pathological
complete response to neoadjuvant therapy for locally advanced nonsmall-
cell lung cancer: clinical implications for the subsequent management of the
brain. Cancer 109, 1668–1675.
Chitale, D., Gong, Y., Taylor, B., Broderick, S., Brennan, C., Somwar, R.,
Golas, B., Wang, L., Motoi, N., Szoke, J., et al. (2009). An integrated genomic
analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Onco-
gene, in press. Published online June 15, 2009. 10.1038/onc.2009.135.
Clevers, H. (2006). Wnt/beta-catenin signaling in development and disease.
Cell 127, 469–480.
Ding, L., Getz, G., Wheeler, D.A., Mardis, E.R., McLellan, M.D., Cibulskis, K.,
Sougnez, C., Greulich, H., Muzny, D.M., Morgan, M.B., et al. (2008). Somatic
mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–
1075.
Doki, Y., Murakami, K., Yamaura, T., Sugiyama, S., Misaki, T., and Saiki, I.
(1999). Mediastinal lymph node metastasis model by orthotopic intrapulmo-
nary implantation of Lewis lung carcinoma cells in mice. Br. J. Cancer 79,
1121–1126.
Feld, R., Rubinstein, L.V., andWeisenberger, T.H. (1984). Sites of recurrence in
resected stage I non-small-cell lung cancer: a guide for future studies. J. Clin.
Oncol. 2, 1352–1358.
Gaspar, L.E. (2004). Brain metastases in lung cancer. Expert Rev. Anticancer
Ther. 4, 259–270.
Gavrilovic, I.T., and Posner, J.B. (2005). Brain metastases: epidemiology and
pathophysiology. J. Neurooncol. 75, 5–14.
Gottardi, C.J., and Gumbiner, B.M. (2004). Distinct molecular forms of beta-
catenin are targeted to adhesive or transcriptional complexes. J. Cell Biol.
167, 339–349.
Hatzis, P., vander Flier, L.G., vanDriel,M.A., Guryev, V., Nielsen, F., Denissov, S.,
Nijman, I.J., Koster, J., Santo, E.E., Welboren, W., et al. (2008). Genome-wide
pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. Mol.
Cell. Biol. 28, 2732–2744.
He, T.C., Sparks, A.B., Rago, C., Hermeking, H., Zawel, L., da Costa, L.T.,
Morin, P.J., Vogelstein, B., and Kinzler, K.W. (1998). Identification of c-MYC
as a target of the APC pathway. Science 281, 1509–1512.
Hess, K.R., Varadhachary, G.R., Taylor, S.H., Wei, W., Raber, M.N., Lenzi, R.,
and Abbruzzese, J.L. (2006). Metastatic patterns in adenocarcinoma. Cancer
106, 1624–1633.
Hoffman, P.C., Mauer, A.M., and Vokes, E.E. (2000). Lung cancer. Lancet 355,
479–485.
Hovanes, K., Li, T.W., Munguia, J.E., Truong, T., Milovanovic, T., Lawrence
Marsh, J., Holcombe, R.F., andWaterman, M.L. (2001). Beta-catenin-sensitive
isoforms of lymphoid enhancer factor-1 are selectively expressed in colon
cancer. Nat. Genet. 28, 53–57.
Husemann, Y., Geigl, J.B., Schubert, F., Musiani, P., Meyer, M., Burghart, E.,
Forni, G., Eils, R., Fehm, T., Riethmuller, G., et al. (2008). Systemic spread is an
early step in breast cancer. Cancer Cell 13, 58–68.Cell 138, 51–62, July 10, 2009 ª2009 Elsevier Inc. 61
Jackson, E.L., Olive, K.P., Tuveson, D.A., Bronson, R., Crowley, D., Brown, M.,
and Jacks, T. (2005). The differential effects of mutant p53 alleles on advanced
murine lung cancer. Cancer Res. 65, 10280–10288.
Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K.,
Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006). The impact
of human EGFR kinase domain mutations on lung tumorigenesis and in vivo
sensitivity to EGFR-targeted therapies. Cancer Cell 9, 485–495.
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R.T., Crowley, D., Tuveson,
D.A., and Jacks, T. (2001). Somatic activation of the K-ras oncogene causes
early onset lung cancer in mice. Nature 410, 1111–1116.
Karnoub, A.E., Dash, A.B., Vo, A.P., Sullivan, A., Brooks, M.W., Bell, G.W.,
Richardson, A.L., Polyak, K., Tubo, R., and Weinberg, R.A. (2007). Mesen-
chymal stem cells within tumour stroma promote breast cancer metastasis.
Nature 449, 557–563.
Karrison, T.G., Ferguson, D.J., and Meier, P. (1999). Dormancy of mammary
carcinoma after mastectomy. J. Natl. Cancer Inst. 91, 80–85.
Kim, C.F., Jackson, E.L., Woolfenden, A.E., Lawrence, S., Babar, I., Vogel, S.,
Crowley, D., Bronson, R.T., and Jacks, T. (2005). Identification of bronchioal-
veolar stem cells in normal lung and lung cancer. Cell 121, 823–835.
Klaus, A., and Birchmeier, W. (2008). Wnt signalling and its impact on develop-
ment and cancer. Nat. Rev. Cancer 8, 387–398.
Klein, C.A., Schmidt-Kittler, O., Schardt, J.A., Pantel, K., Speicher, M.R., and
Riethmuller, G. (1999). Comparative genomic hybridization, loss of heterozy-
gosity, and DNA sequence analysis of single cells. Proc. Natl. Acad. Sci.
USA 96, 4494–4499.
Koizumi, F., Shimoyama, T., Taguchi, F., Saijo, N., andNishio, K. (2005). Estab-
lishment of a human non-small cell lung cancer cell line resistant to gefitinib.
Int. J. Cancer 116, 36–44.
Korinek, V., Barker, N., Morin, P.J., van Wichen, D., de Weger, R., Kinzler,
K.W., Vogelstein, B., and Clevers, H. (1997). Constitutive transcriptional acti-
vation by a beta-catenin-Tcf complex in APC/ colon carcinoma. Science
275, 1784–1787.
Licchesi, J.D., Westra, W.H., Hooker, C.M., Machida, E.O., Baylin, S.B., and
Herman, J.G. (2008). Epigenetic alteration of Wnt pathway antagonists in
progressive glandular neoplasia of the lung. Carcinogenesis 29, 895–904.
Logan, C.Y., and Nusse, R. (2004). The Wnt signaling pathway in development
and disease. Annu. Rev. Cell Dev. Biol. 20, 781–810.
Martini, N., Bains, M.S., Burt, M.E., Zakowski, M.F., McCormack, P., Rusch,
V.W., and Ginsberg, R.J. (1995). Incidence of local recurrence and second
primary tumors in resected stage I lung cancer. J. Thorac. Cardiovasc. Surg.
109, 120–129.
Mazieres, J., He, B., You, L., Xu, Z., and Jablons, D.M. (2005). Wnt signaling in
lung cancer. Cancer Lett. 222, 1–10.
Minn, A.J., Gupta, G.P., Siegel, P.M., Bos, P.D., Shu, W., Giri, D.D., Viale, A.,
Olshen, A.B., Gerald, W.L., and Massague´, J. (2005a). Genes that mediate
breast cancer metastasis to lung. Nature 436, 518–524.
Minn, A.J., Kang, Y., Serganova, I., Gupta, G.P., Giri, D.D., Doubrovin, M.,
Ponomarev, V., Gerald, W.L., Blasberg, R., and Massague´, J. (2005b). Distinct
organ-specific metastatic potential of individual breast cancer cells and
primary tumors. J. Clin. Invest. 115, 44–55.
Moon, R.T., Kohn, A.D., De Ferrari, G.V., and Kaykas, A. (2004).WNT and beta-
catenin signalling: diseases and therapies. Nat. Rev. Genet. 5, 691–701.
Morin, P.J., Sparks, A.B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B.,
and Kinzler, K.W. (1997). Activation of beta-catenin-Tcf signaling in colon
cancer by mutations in beta-catenin or APC. Science 275, 1787–1790.
Nguyen, D.X., Bos, P.D., and Massague´, J. (2009). Metastasis: from dissemi-
nation to organ-specific colonization. Nat. Rev. Cancer 9, 274–284.
Omuro, A.M., Kris, M.G., Miller, V.A., Franceschi, E., Shah, N., Milton, D.T., and
Abrey, L.E. (2005). High incidence of disease recurrence in the brain and
leptomeninges in patients with nonsmall cell lung carcinoma after response
to gefitinib. Cancer 103, 2344–2348.62 Cell 138, 51–62, July 10, 2009 ª2009 Elsevier Inc.Padua, D., Zhang, X.H., Wang, Q., Nadal, C., Gerald, W.L., Gomis, R.R., and
Massague´, J. (2008). TGFbeta primes breast tumors for lung metastasis
seeding through angiopoietin-like 4. Cell 133, 66–77.
Phelps, R.M., Johnson, B.E., Ihde, D.C., Gazdar, A.F., Carbone, D.P., McClin-
tock, P.R., Linnoila, R.I., Matthews, M.J., Bunn, P.A., Jr., Carney, D., et al.
(1996). NCI-Navy Medical Oncology Branch cell line data base. J. Cell.
Biochem. Suppl. 24, 32–91.
Polakis, P. (2007). Themanyways ofWnt in cancer. Curr. Opin. Genet. Dev. 17,
45–51.
Politi, K., Zakowski, M.F., Fan, P.D., Schonfeld, E.A., Pao, W., and Varmus,
H.E. (2006). Lung adenocarcinomas induced in mice by mutant EGF receptors
found in human lung cancers respond to a tyrosine kinase inhibitor or to down-
regulation of the receptors. Genes Dev. 20, 1496–1510.
Rodenhuis, S., Slebos, R.J., Boot, A.J., Evers, S.G., Mooi, W.J., Wagenaar,
S.S., van Bodegom, P.C., and Bos, J.L. (1988). Incidence and possible clinical
significance of K-ras oncogene activation in adenocarcinoma of the human
lung. Cancer Res. 48, 5738–5741.
Sasaki, Y., Shinkai, T., Eguchi, K., Tamura, T., Ohe, Y., Ohmori, T., and Saijo,
N. (1991). Prediction of the antitumor activity of new platinum analogs based
on their ex vivo pharmacodynamics as determined by bioassay. Cancer
Chemother. Pharmacol. 27, 263–270.
Schmidt-Kittler, O., Ragg, T., Daskalakis, A., Granzow, M., Ahr, A., Blanken-
stein, T.J., Kaufmann, M., Diebold, J., Arnholdt, H., Muller, P., et al. (2003).
From latent disseminated cells to overt metastasis: genetic analysis of
systemic breast cancer progression. Proc. Natl. Acad. Sci. USA 100, 7737–
7742.
Sharma, S.V., Bell, D.W., Settleman, J., and Haber, D.A. (2007). Epidermal
growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169–181.
Shedden, K., Taylor, J.M., Enkemann, S.A., Tsao, M.S., Yeatman, T.J., Gerald,
W.L., Eschrich, S., Jurisica, I., Giordano, T.J., Misek, D.E., et al. (2008). Gene
expression-based survival prediction in lung adenocarcinoma: a multi-site,
blinded validation study. Nat. Med. 14, 822–827.
Shu, W., Guttentag, S., Wang, Z., Andl, T., Ballard, P., Lu, M.M., Piccolo, S.,
Birchmeier, W., Whitsett, J.A., Millar, S.E., et al. (2005). Wnt/beta-catenin
signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate prox-
imal-distal patterning in the lung. Dev. Biol. 283, 226–239.
Sweet-Cordero, A., Mukherjee, S., Subramanian, A., You, H., Roix, J.J., Ladd-
Acosta, C., Mesirov, J., Golub, T.R., and Jacks, T. (2005). An oncogenic
KRAS2 expression signature identified by cross-species gene-expression
analysis. Nat. Genet. 37, 48–55.
ten Dijke, P., Korchynskyi, O., Valdimarsdottir, G., and Goumans, M.J. (2003).
Controlling cell fate by bone morphogenetic protein receptors. Mol. Cell.
Endocrinol. 211, 105–113.
Thomas, A.J., Rock, J.P., Johnson, C.C., Weiss, L., Jacobsen, G., and Rose-
nblum,M.L. (2000). Survival of patients with synchronous brain metastases: an
epidemiological study in southeastern Michigan. J. Neurosurg. 93, 927–931.
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone,
A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.P., et al. (2002). The
beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colo-
rectal cancer cells. Cell 111, 241–250.
Varga, A.C., and Wrana, J.L. (2005). The disparate role of BMP in stem cell
biology. Oncogene 24, 5713–5721.
Xu, L., Shen, S.S., Hoshida, Y., Subramanian, A., Ross, K., Brunet, J.P.,
Wagner, S.N., Ramaswamy, S., Mesirov, J.P., and Hynes, R.O. (2008). Gene
expression changes in an animal melanoma model correlate with aggressive-
ness of human melanoma metastases. Mol. Cancer Res. 6, 760–769.
Zhang, Y., Goss, A.M., Cohen, E.D., Kadzik, R., Lepore, J.J., Muthukumarasw-
amy, K., Yang, J., DeMayo, F.J., Whitsett, J.A., Parmacek, M.S., et al. (2008). A
Gata6-Wnt pathway required for epithelial stem cell development and airway
regeneration. Nat. Genet. 40, 862–870.
Zheng, S., El-Naggar, A.K., Kim, E.S., Kurie, J.M., and Lozano, G. (2007). A
genetic mouse model for metastatic lung cancer with gender differences in
survival. Oncogene 26, 6896–6904.
